Active Ingredient History
Pidilizumab is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 1)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Colonic Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 2)
Hepatitis C, Chronic (Phase 1/Phase 2)
Lymphoma (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 2)
Multiple Myeloma (Phase 2)
Ovarian Neoplasms (Phase 1)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Sarcoma (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue